Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis

Mycopathologia

Volumn 166, Issue 2, 2008, Pages 83-86

  Ananda Rajah, M R ^a   Grigg, A ^a   Slavin, M A ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Acute leukaemia; Posaconazole; Scedosporium prolificans

Indexed keywords

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; POSACONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ARTICLE; CASE REPORT; FATALITY; HUMAN; LEUKEMIA; MALE; MIDDLE AGED; MYCETOMA; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; SCEDOSPORIUM;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; HUMANS; LEUKEMIA; MADUROMYCOSIS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PYRIMIDINES; RECURRENCE; SCEDOSPORIUM; TRIAZOLES;

SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS;

EID: 46949103068     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-008-9131-2     Document Type: Article

References (21)

1. Cornely OA, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-59. doi: 10.1056/NEJMoa061094.
2. Ullmann AJ, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-47. doi: 10.1056/NEJMoa061098.
3. Imhof A, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743-6. doi: 10.1086/423274.
4. Kantarjian HM, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-61.
5. Husain S, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89-99. doi: 10.1086/426445.
6. Lamaris GA, et al. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis 2006;43:1580-4. doi: 10.1086/509579.
7. Cooley L, et al. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis. 2007;13:1170-7.
8. Lionakis MS, et al. The significance of blood cultures positive for emerging saprophytic moulds in cancer patients. Clin Microbiol Infect. 2004;10:922-5. doi: 10.1111/j.1469-0691.2004.00933.x.
9. Howden BP, et al. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111-3.
10. Li JY, et al. Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis in a long-term renal transplant recipient. Transpl Infect Dis. 2008;10:63-5.
11. Steinbach WJ, et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol. 2003;41:3981-5. doi: 10.1128/JCM.41.8.3981-3985.2003.
12. Singh N, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006;81:320-6. doi: 10.1097/01.tp.0000202421.94822.f7.
13. Carrillo AJ, et al. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother. 2001;45:2151-3. doi: 10.1128/AAC.45.7.2151-2153.2001.
14. Cuenca-Estrella M, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother. 2006;50:917-21. doi: 10.1128/AAC.50.3.917-921.2006.
15. Siwek GT, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:584-7. doi: 10.1086/422723.
16. Kontoyiannis DP, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350-60. doi: 10.1086/428780.
17. Maertens J, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24:307-12. doi: 10.1038/sj.bmt. 1701885.
18. Walsh TJ, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2-12. doi: 10.1086/508774.
19. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27:1627-36. doi: 10.1592/phco.27.12.1627.
20. Ullmann A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50:658-66. doi: 10.1128/AAC.50.2.658-666.2006.
21. Mullane K, et al. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis. 2007;9:89-96. doi: 10.1111/j.1399-3062.2007.00208.x.